Floatz logo

Therapeutic Allogeneic Lymphocytes

Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Fred Hutchinson Cancer CenterCell therapyPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
89/ 100

Competitive context

141 Active assets in the Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
FILGRASTIM
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Therapeutic Allogeneic Lymphocytes is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Relapsing Chronic Myelogenous LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →